Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) closed the day trading at $39.56 up 2.49% from the previous closing price of $38.6. In other words, the price has increased by $2.49 from its previous closing price. On the day, 0.99 million shares were traded. KNSA stock price reached its highest trading level at $39.69 during the session, while it also had its lowest trading level at $37.56.
Ratios:
For a better understanding of KNSA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.47. For the most recent quarter (mrq), Quick Ratio is recorded 3.51 and its Current Ratio is at 3.85. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, TD Cowen on September 29, 2025, initiated with a Buy rating and assigned the stock a target price of $60.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $40.
On September 13, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $40.Jefferies initiated its Buy rating on September 13, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 08 ’26 when Ragosa Mark sold 12,000 shares for $41.89 per share. The transaction valued at 502,680 led to the insider holds 19,086 shares of the business.
Quart Barry D sold 20,129 shares of KNSA for $835,555 on Dec 15 ’25. The Director now owns 12,546 shares after completing the transaction at $41.51 per share. On Dec 15 ’25, another insider, Tessari Eben, who serves as the CHIEF OPERATING OFFICER of the company, sold 12,048 shares for $41.56 each. As a result, the insider received 500,715 and left with 16,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KNSA now has a Market Capitalization of 2998480384 and an Enterprise Value of 2656096256. As of this moment, Kiniksa’s Price-to-Earnings (P/E) ratio for their current fiscal year is 88.22, and their Forward P/E ratio for the next fiscal year is 24.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.01 while its Price-to-Book (P/B) ratio in mrq is 5.57. Its current Enterprise Value per Revenue stands at 4.442 whereas that against EBITDA is 67.004.
Stock Price History:
The Beta on a monthly basis for KNSA is 0.05, which has changed by 1.0989668 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, KNSA has reached a high of $44.42, while it has fallen to a 52-week low of $18.12. The 50-Day Moving Average of the stock is -3.81%, while the 200-Day Moving Average is calculated to be 19.54%.
Shares Statistics:
Over the past 3-months, KNSA traded about 463.21K shares per day on average, while over the past 10 days, KNSA traded about 589300 shares per day. A total of 44.79M shares are outstanding, with a floating share count of 43.34M. Insiders hold about 42.83% of the company’s shares, while institutions hold 54.79% stake in the company. Shares short for KNSA as of 1767139200 were 3570712 with a Short Ratio of 7.71, compared to 1764288000 on 2801537. Therefore, it implies a Short% of Shares Outstanding of 3570712 and a Short% of Float of 8.55.
Earnings Estimates
Kiniksa Pharmaceuticals International Plc (KNSA) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.33, with high estimates of $0.33 and low estimates of $0.33.
Analysts are recommending an EPS of between $1.42 and $0.86 for the fiscal current year, implying an average EPS of $1.11. EPS for the following year is $1.7, with 5.0 analysts recommending between $2.42 and $1.26.
Revenue Estimates
7 analysts predict $197.09M in revenue. The current quarter. It ranges from a high estimate of $202.1M to a low estimate of $180.4M. As of. The current estimate, Kiniksa Pharmaceuticals International Plc’s year-ago sales were $122.54MFor the next quarter, 7 analysts are estimating revenue of $204.44M. There is a high estimate of $212.2M for the next quarter, whereas the lowest estimate is $190M.
A total of 7 analysts have provided revenue estimates for KNSA’s current fiscal year. The highest revenue estimate was $677.5M, while the lowest revenue estimate was $645M, resulting in an average revenue estimate of $671M. In the same quarter a year ago, actual revenue was $423.24MBased on 7 analysts’ estimates, the company’s revenue will be $886.44M in the next fiscal year. The high estimate is $917.45M and the low estimate is $800M.
